West Pharmaceutical Services reported second-quarter 2026 net sales of $872.3 million, up 13.8% from a year earlier, with organic growth of 12.7%.
Diluted earnings per share rose 18.1% to $2.15, while adjusted diluted EPS climbed 28.8% to $2.37.
Operating cash flow came in at $213.9 million. After $85.9 million of capital expenditures, free cash flow was $128.0 million.
The company’s proprietary products segment generated $722.6 million in sales, up 16.6% year over year and 15.5% organically. Within that segment, high-value product components posted $424.1 million in sales, a 19.4% increase, and high-value product delivery devices rose 29.6% to $131.2 million. Standard products increased 2.4% to $167.3 million.
West Vantage sales were $149.7 million, up 2.0% from the prior-year quarter.
For the first six months of 2026, West repurchased 1.8 million shares for $454.3 million at an average price of $258.03 per share.
The board declared a third-quarter dividend of $0.22 per share.
West raised its full-year 2026 net sales guidance to $3.345 billion to $3.380 billion, compared with the prior range of $3.295 billion to $3.350 billion. The new range implies reported growth of 8.8% to 10.0% and organic growth of 10.0% to 11.0%.
Full-year adjusted diluted EPS guidance was increased to $8.85 to $9.05, from the prior range of $8.40 to $8.75.
For the third quarter, West projected net sales of $820 million to $835 million, with adjusted diluted EPS of $2.14 to $2.24. The company said third-quarter sales would rise 1.9% to 3.8% reported and 7.0% to 8.9% organically. Today the company's shares have moved 0.04% to a price of $358.55. For more information, read the company's full 8-K submission here.
